Retroviral Particle Production
Retroviral Particle Production - Related Videos
03:36
Production of Retroviral Particles for Gene Transfer
0 Views •
2026
Source: Zjablovskaja, P., et al., Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells. J. Vis. Exp. (2018)This video demonstrates the production of recombinant retroviral particles by transfecting human kidney-derived packaging cells, enabling stable gene delivery to target cells for downstream applications such as genetic modification, functional assays, or lineage differentiation studies.
09:19
Recombinant Retroviral Production and Infection of B Cells
0 Views •
Cited by 2 •
2011
An efficient system of structure and function analysis of a gene in an ex vivo culture of splenic B-lymphocytes is described. This method takes advantage of recombinant retroviral production in a helper free, ecotrophic packaging cell line. Stable, heritable expression of a gene of interest within primary lymphocytes is achieved leading to generation of surface antibodies on B cells undergoing class switch recombination.
04:12
Production and Purification of Recombinant Hepatitis B Virus Particles
0 Views •
2026
Source: Nishitsuji, H., et al. Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle. J. Vis. Exp. (2017)This video demonstrates the production and purification of recombinant Hepatitis B virus particles, enabling safe, replication-deficient viral preparations for studying early infection events and for high-throughput antiviral drug screening applications.
03:41
Production of Virus-like Particles in Engineered E. coli
0 Views •
2026
Source: Chen, Z., et al. Making Conjugation-induced Fluorescent PEGylated Virus-like Particles by Dibromomaleimide-disulfide Chemistry. J. Vis. Exp. (2018)This video demonstrates the method for the controlled expression of the bacteriophage Qβ coat protein in engineered E. coli. The resulting proteins self-assemble into virus-like particles, which are harvested for downstream bioconjugation.
03:26
Reverse Transcriptase Activity as a Marker for Virus-Like Particle Production
0 Views •
2026
Source: Scarborough, R. J., et al. Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy. J. Vis. Exp. (2016).This video demonstrates a reverse transcriptase (RT) assay to assess the effect of a test RNA on virus-like particle (VLP) production. Cells are co-transfected with plasmids, and RT activity is measured as a quantitative indicator of VLP output. A decrease in RT activity reflects suppression of viral gene expression by the test RNA.
FAQs
Producer-cell output depends on coordinated expression of the vector genome, Gag and Pol proteins, and an envelope glycoprotein. The vector genome provides the RNA to be packaged, while Gag and Pol supply structural and enzymatic functions needed for particle formation. Keeping these functions on separate components supports controlled assembly and helps distinguish the transferable genetic material from the production machinery.
Separating these functions helps limit the possibility of generating replication-competent virus, because the particle-producing system does not place all required functions in one transferable genetic unit. This arrangement also allows the vector genome to be packaged while the structural and enzymatic components remain associated with production. Component separation is therefore central to safety-oriented design and reproducible preparation.
After the supplied components are expressed in producer cells, they assemble into particles that package the vector RNA. The assembled particles then bud from the cell membrane, producing material capable of transferring genetic information to target cells. These linked events connect intracellular component expression with the generation of particles suitable for downstream gene-transfer experiments.
Integrating retroviral vectors can support stable expression of delivered genetic material, which is useful when researchers need the introduced sequence to remain active over time. The overview also indicates that this capability can extend to both dividing and nondividing cells. Consequently, integration broadens experimental designs beyond short-term delivery and supports persistent labeling or functional studies.
The workflow begins by supplying producer cells with separate components for the vector genome, Gag and Pol proteins, and an envelope glycoprotein. Cells then assemble particles, package the vector RNA, and release particles by budding from the membrane. The resulting preparation is followed by quality testing, which helps assess reproducibility and limit replication-competent virus.
Two stated priorities are limiting replication-competent virus and obtaining reproducible preparations. Researchers address these priorities through separation of the production components and quality testing of the resulting material. These checks are important because gene-transfer experiments depend not only on particle generation, but also on confidence that preparations behave consistently and meet the intended safety-related criteria.
The resulting particles support gene transfer for functional genomics, cell labeling, disease modeling, and gene therapy research. Their ability to deliver genetic material, together with the stable expression possible from integrating vectors, makes them useful for studying gene function and cellular behavior. The same production framework therefore connects molecular delivery with broader biological and translational investigations.